Please assess the completion status of the following clinical trial:

Trial Title: VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~A subject must meet all of the following criteria:~* 18 to 50 years old~* Available for clinic visits for 24 months after enrollment~* Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process~* Able and willing to complete the informed consent process~* Willing to donate blood for sample storage to be used for future research~* In good general health without clinically significant medical history~* Physical examination and laboratory results without clinically significant findings and a Body Mass Index (BMI) less than or equal to 40 within the 56 days prior to enrollment~* Agrees not to receive licensed or investigational flavivirus vaccines through 4 weeks after last product administration~* Laboratory Criteria within 56 days prior to enrollment:~  * Hemoglobin within institutional normal limits or accompanied by the site Principal Investigator (PI) or designee approval~ * WBC and differential either within institutional normal range or accompanied by site PI or designee approval~ * Total lymphocyte count greater than or equal to 800 cells/mm\^3~ * Platelets = 125,000 - 500,000/mm\^3~ * Alanine aminotransferase (ALT) less than or equal to 1.25 x institutional upper limit of normal (ULN)~ * Serum creatinine less than or equal to 1.1 x institutional ULN~ * Negative for HIV infection by an FDA approved method of detection~* Criteria applicable to women of childbearing potential:~  * Negative human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) on day of enrollment~ * Agrees to use an effective means of birth control from at least 21 days prior to enrollment through 12 weeks after the last study vaccination~EXCLUSION CRITERIA:~A subject will be excluded if one or more of the following conditions apply:~* Female-specific: Breast-feeding or planning to become pregnant while participating through 12 weeks after the last study vaccination~* Subject has received any of the following:~  * More than 10 days of systemic immunosuppressive medications or cytotoxic medications within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment~ * Blood products within 16 weeks prior to enrollment~ * Inactivated vaccines within 2 weeks prior to enrollment~ * Live attenuated vaccines within 4 weeks prior to enrollment~ * Investigational research products within 4 weeks prior to enrollment or planning to receive investigational products while on the study~ * Current allergen immunotherapy with antigen injections, unless on maintenance schedule~ * Current anti-TB prophylaxis or therapy~* Subject has a history of any of the following clinically significant conditions:~  * Laboratory confirmed ZIKV infection by self-report at the time of enrollment~ * Serious reactions to vaccines that preclude receipt of study vaccinations as determined by the site investigator~ * Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema~ * Asthma that is not well controlled~ * Diabetes mellitus (type I or II), with the exception of gestational diabetes~ * Evidence of autoimmune disease or immunodeficiency~ * Idiopathic urticaria within the past year~ * Hypertension that is not well controlled~ * Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws~ * Malignancy that is active or history of malignancy that is likely to recur during the period of the study~ * Seizure disorder other than: 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years~ * Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen~ * Guillain-Barre Syndrome, Bell's palsy or similar neurological conditions~ * Psychiatric condition that precludes compliance with the protocol; past or present psychoses; or within 5 years prior to enrollment, a history of suicide plan or attempt~ * Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): ZIKV DNA vaccine administered IM via needle and syringe at a single dosage of 4 mg on Day 0, week 4 and week 8.
- Group 2 (Type: EXPERIMENTAL): ZIKV DNA vaccine administered IM via needle and syringe as a split dose of two .5 ml injections on Day 0, week 4 and week 8.
- Group 3 (Type: EXPERIMENTAL): ZIKV DNA vaccine administered IM via needle-free injection device, PharmaJet, as a split dose of two .5 ml injections on Day 0, week 4 and week 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete